In Brief: Indena
This article was originally published in The Tan Sheet
Executive Summary
Indena: Signs agreement with Institute of Botany of Nanjing Botanical Garden, China, to evaluate the "potential antimicrobial and antiviral properties" of 120 "traditional Chinese medicinal plants as potential therapeutic products." The botanical derivative "research, development and production" company, based in Italy, investigates uses of "plant-derived active principles for use in the pharmaceutical, cosmetics and health food industries"...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning